Overview

Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients With Multiple Sclerosis

Status:
Recruiting

Trial end date:
2021-11-01

Target enrollment:

Participant gender:

Summary

This study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale Lower Limb Muscle Tone-6 [MAS LLMT-6]) in participants with multiple sclerosis (MS) who have not achieved adequate relief from spasticity with other antispasticity medications.

Phase:

Phase 3

Details

Lead Sponsor:

GW Pharmaceuticals Ltd.

Treatments:

Nabiximols